Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The apolipoprotein E type 4 allele ( APOE -ε4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE -ε4 alleles in 42 families with late onset AD. Thus APOE -ε4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE -ε4 was virtually sufficient to cause AD by age 80.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
91 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationMiller, R. G. (1981) · Cited by 3,336
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citationNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14
Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., White, J. A., Bonnycastle, L., Weber, J. L., Alonso, M. E., et al. (1992) · Science · doi:10.1126/science.1411576 · Cited by 946
Research works printed but not linked: 3
- SAS/STAT User's Guide Release 6.03 Edition (1988).
- SAS User's Guide: Statistics Version 5 Edition (1985).
- 10.1073/pnas.90.5.1977 · DOI · Paper page
Cited by
Items 301–400 of 1,689
Shearman, M. S., Ragan, C. I., & Iversen, L. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1470 · Cited by 412
Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders
DeKosky, S. T., & Marek, K. (2003) · Science · doi:10.1126/science.1090349 · Cited by 406
Probing the biology of Alzheimer’s disease in mice
Ashe, K. H., & Zahs, K. R. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.031 · Cited by 413
Ritchie, K., & Lovestone, S. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11667-9 · Cited by 387
Apolipoprotein e sets the stage: response to injury triggers neuropathology
Mahley, R. W., & Huang, Y. (2012) · Neuron · doi:10.1016/j.neuron.2012.11.020 · Cited by 412
Epidemiology of Dementia and Alzheimer's Disease
Hendrie, H. C. (1998) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199821001-00002 · Cited by 412
Glial contributions to neurodegeneration in tauopathies
Leyns, C. E. G., & Holtzman, D. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0192-x · Cited by 409
“associated with a 4–12-fold increased risk based on allele dosage [85, 86].”
BackgroundALZHEIMER'S DISEASE: Genetic Studies and Transgenic Models
Price, D. L., Tanzi, R. E., Borchelt, D. R., & Sisodia, S. S. (1998) · Annual Review of Genetics · doi:10.1146/annurev.genet.32.1.461 · Cited by 406
Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review
Reitz, C. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/369808 · Cited by 376
“The apolipoprotein E (APOE) gene, which was identified as the first susceptibility gene for late-onset AD, is the major genetic risk factor (population attributable risk: ∼20%) [27, 28].”
BackgroundNatural products as a source of Alzheimer's drug leads
Williams, P., Sorribas, A., & Howes, M.-J. R. (2011) · Nat. Prod. Rep. · doi:10.1039/c0np00027b · Cited by 404
Sanan, D. A., Weisgraber, K. H., Russell, S. J., Mahley, R. W., Huang, D., Saunders, A., Schmechel, D., Wisniewski, T., Frangione, B., & Roses, A. D. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117407 · Cited by 404
Self-citationBrecht, W. J., Harris, F. M., Chang, S., Tesseur, I., Yu, G.-Q., Xu, Q., Dee Fish, J., Wyss-Coray, T., Buttini, M., Mucke, L., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4315-03.2004 · Cited by 403
“Individuals with two copies of the ⑀4 allele have a 50 –90% chance of developing AD by the age of 85 years, and those with one copy have an ϳ45% chance (Corder et al., 1993; Farrer et al., 1997).”
BackgroundResultInfluentialThe amyloid cascade hypothesis: are we poised for success or failure?
Karran, E., & De Strooper, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13632 · Cited by 402
Targa Dias Anastacio, H., Matosin, N., & Ooi, L. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02024-7 · Cited by 401
“The APOE ε4 allele is the major genetic risk factor for LOAD, elevating the risk of developing the disease 3 to 10-fold, compared to the general population [92].”
BackgroundReiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500579102 · Cited by 401
Self-citationWatson, G. S., & Craft, S. (2003) · CNS Drugs · doi:10.2165/00023210-200317010-00003 · Cited by 397
Slooter, A. J. C., Cruts, M., Kalmijn, S., Hofman, A., Breteler, M. M. B., Van Broeckhoven, C., & van Duijn, C. M. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.964 · Cited by 399
“In addition, it is still controversial whether the e2 allele exerts a protective effect,(11,12) whether a family history of dementia further increases the e4related risk,(2,3) and whether the APOE genotype is a determinant of the patient’s age at the onset of dementia.(1,13) Thus, reliable estimates of the risk of dem…”
Background(Pre)diabetes, brain aging, and cognition
S. Roriz-Filho, J., Sá-Roriz, T. M., Rosset, I., Camozzato, A. L., Santos, A. C., Chaves, M. L. F., Moriguti, J. C., & Roriz-Cruz, M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.12.003 · Cited by 386
“of the APOEɛ4 is associated with an increased incidence of Alzheimer's disease [212], it seems that insulin resistance is only a significant risk”
Cuppens, H., Lin, W., Jaspers, M., Costes, B., Teng, H., Vankeerberghen, A., Jorissen, M., Droogmans, G., Reynaert, I., Goossens, M., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci639 · Cited by 397
Calcium Hypothesis of Alzheimer's Disease and Brain Aginga
KHACHATURIAN, Z. S. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb44398.x · Cited by 392
Structural imaging of hippocampal subfields in healthy aging and Alzheimer’s disease
de Flores, R., La Joie, R., & Chételat, G. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.033 · Cited by 363
“The ε4 allele of the apolipoprotein E (APOE4) is the largest genetic risk factor for sporadic AD (Corder et al., 1993; Farrer et al., 1997; Genin et al., 2011), and its detrimental effect (as compared to the more frequent ε3 allele) is dose-dependent: odds ratio for AD are 3.”
BackgroundMiners, J. S., Baig, S., Palmer, J., Palmer, L. E., Kehoe, P. G., & Love, S. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00132.x · Cited by 381
“We found a significant association between NEP labeling and APOE genotype, the only well-established genetic risk factor for both AD and CAA (30, 33, 53, 129, 140).”
A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease
Roses, A. D., Lutz, M. W., Amrine-Madsen, H., Saunders, A. M., Crenshaw, D. G., Sundseth, S. S., Huentelman, M. J., Welsh-Bohmer, K. A., & Reiman, E. M. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.69 · Cited by 391
Self-citationApolipoprotein E in Alzheimer's Disease: An Update
Yu, J.-T., Tan, L., & Hardy, J. (2014) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071013-014300 · Cited by 394
“GENETICS OF APOE IN ALZHEIMER’S DISEASE In 1993, genetic analysis identified APOE4 as the major risk factor for AD (Corder et al. 1993) and immediately thereafter identified APOE2 as being protective against disease (Chartier-Harlin et al. 1994).”
BackgroundHuang, Y., Liu, X. Q., Wyss-Coray, T., Brecht, W. J., Sanan, D. A., & Mahley, R. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151254698 · Cited by 392
Preventing Alzheimer’s Disease
Selkoe, D. J. (2012) · Science · doi:10.1126/science.1228541 · Cited by 376
THE MAMMALIAN LOW-DENSITY LIPOPROTEIN RECEPTOR FAMILY
Hussain, M. M., Strickland, D. K., & Bakillah, A. (1999) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.19.1.141 · Cited by 377
Galantamine: A Review of its Use in Alzheimer??s Disease
Scott, L. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200060050-00008 · Cited by 383
“tors, Down’s syndrome and the presence of the apolipoprotein E ε4 (ApoE ε4) gene allele have been shown to have a strong correlation with the development of AD.[18-25] The cognitive deficits seen in patients with AD are thought to be primarily related to the degeneration of cholinergic neurons in the cortex and hippoc…”
Rondeau, V., Commenges, D., Jacqmin-Gadda, H., & Dartigues, J.-F. (2000) · American Journal of Epidemiology · doi:10.1093/aje/152.1.59 · Cited by 381
“) Although much effort has been devoted to identifying the genetic determinants of Alzheimer’s disease (1), it is likely that certain environmental factors play a role in this disease.”
BackgroundSusceptibility Locus for Alzheimer's Disease on Chromosome 10
Myers, A., Holmans, P., Marshall, H., Kwon, J., Meyer, D., Ramic, D., Shears, S., Booth, J., DeVrieze, F. W., Crook, R., et al. (2000) · Science · doi:10.1126/science.290.5500.2304 · Cited by 386
Episodic memory in normal aging and Alzheimer disease: Insights from imaging and behavioral studies
Tromp, D., Dufour, A., Lithfous, S., Pebayle, T., & Després, O. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.08.006 · Cited by 390
Injured Brains and Adaptive Networks: The Benefits and Costs of Hyperconnectivity
Hillary, F. G., & Grafman, J. H. (2017) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2017.03.003 · Cited by 366
“The APOE e4 allele is a predictor of increased risk for neurodegeneration later in life [135].”
Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study
Seshadri, S., & Wolf, P. A. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70291-0 · Cited by 369
Synaptopathies: synaptic dysfunction in neurological disorders – A review from students to students
Lepeta, K., Lourenco, M. V., Schweitzer, B. C., Martino Adami, P. V., Banerjee, P., Catuara‐Solarz, S., de La Fuente Revenga, M., Guillem, A. M., Haidar, M., Ijomone, O. M., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13713 · Cited by 386
“Notably, APOE4 appears to impair synapses, at least in part, through the action of Ab oligomers and tau (Andrews-Zwilling et al. 2010; Koffie et al. 2012).”
InfluentialTherapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
Deficiency of ABCA1 Impairs Apolipoprotein E Metabolism in Brain
Hirsch-Reinshagen, V., Zhou, S., Burgess, B. L., Bernier, L., McIsaac, S. A., Chan, J. Y., Tansley, G. H., Cohn, J. S., Hayden, M. R., & Wellington, C. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407962200 · Cited by 385
Davies, G., Armstrong, N., Bis, J. C., Bressler, J., Chouraki, V, Giddaluru, S., Hofer, E., Ibrahim-Verbaas, C. A., Kirin, M., Lahti, J., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.188 · Cited by 384
Candidate Gene–Environment Interaction Research: Reflections and Recommendations
Dick, D. M., Agrawal, A., Keller, M. C., Adkins, A., Aliev, F., Monroe, S., Hewitt, J. K., Kendler, K. S., & Sher, K. J. (2015) · Perspectives on Psychological Science · doi:10.1177/1745691614556682 · Cited by 361
“For example, the ε2/ε3/ε4 polymorphism at the Apolipoprotein E locus is a known and important risk factor for Alzheimer’s and coronary heart disease (Corder et al., 1993; Ward et al., 2009).”
BackgroundTooth loss, dementia and neuropathology in the Nun Study
Stein, P. S., Desrosiers, M., Donegan, S. J., Yepes, J. F., & Kryscio, R. J. (2007) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2007.0046 · Cited by 375
Clusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies
Foster, E. M., Dangla-Valls, A., Lovestone, S., Ribe, E. M., & Buckley, N. J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00164 · Cited by 381
Jung, C.-R., Lin, Y.-T., & Hwang, B.-F. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-140855 · Cited by 380
Cataldo, A. M., Barnett, J. L., Berman, S. A., Li, J., Quarless, S., Bursztajn, S., Lippa, C., & Nixon, R. A. (1995) · Neuron · doi:10.1016/0896-6273(95)90324-0 · Cited by 379
Webers, A., Heneka, M. T., & Gleeson, P. A. (2020) · Immunology & Cell Biology · doi:10.1111/imcb.12301 · Cited by 367
A potential role for apoptosis in neurodegeneration and Alzheimer's disease
Cotman, C. W., & Anderson, A. J. (1995) · Molecular Neurobiology · doi:10.1007/bf02740836 · Cited by 378
Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease
Gomez‐Isla, T., West, H. L., Rebeck, G. W., Harr, S. D., Growdon, J. H., Locascio, J. J., Perls, T. T., Lipsitz, L. A., & Hyman, B. T. (1996) · Annals of Neurology · doi:10.1002/ana.410390110 · Cited by 378
Aggleton, J. P., Pralus, A., Nelson, A. J. D., & Hornberger, M. (2016) · Brain · doi:10.1093/brain/aww083 · Cited by 378
The presenilins and Alzheimer's disease
Hutton, M. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.10.1639 · Cited by 368
“The inheritance of one or two copies of the ApoE4 allele increases the risk of developing AD that is not i herited in an autosomal dominant fashion (4).”
Backgroundα-synuclein in the pathophysiology of Alzheimer’s disease
Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374
Zhao, J., Fu, Y., Yamazaki, Y., Ren, Y., Davis, M. D., Liu, C.-C., Lu, W., Wang, X., Chen, K., Cherukuri, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19264-0 · Cited by 374
Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease
Gouras, G. K., Tampellini, D., Takahashi, R. H., & Capetillo-Zarate, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0679-9 · Cited by 372
“At the same time, the most important genetic risk factor for the development of AD is apolipoprotein E (apoE) [30, 166].”
fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease
Bondi, M. W., Houston, W. S., Eyler, L. T., & Brown, G. G. (2005) · Neurology · doi:10.1212/01.wnl.0000150885.00929.7e · Cited by 372
Hua, X., Leow, A. D., Parikshak, N., Lee, S., Chiang, M.-C., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.07.013 · Cited by 360
“Carriers of an ApoE2 gene (which confers lower risk for AD than that of the general population) or an ApoE4 gene (which increases risk for developing AD relative to that of the general population) were compared with homozygous ApoE3, which is the commonest genotype (Corder et al., 1993; Saunders et al., 1993; Roses an…”
Evans, D. A., Bennett, D. A., Wilson, R. S., Bienias, J. L., Morris, M. C., Scherr, P. A., Hebert, L. E., Aggarwal, N., Beckett, L. A., Joglekar, R., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.2.185 · Cited by 370
“Most studies in white populations have found that the APOE 4 allele is associated with strongly increased risk of AD.(5-7) Although the relation has been less extensively examined in black populations, the results of this study are generally consistent with previous studies.”
ResultOverexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease
Wahrle, S. E., Jiang, H., Parsadanian, M., Kim, J., Li, A., Knoten, A., Jain, S., Hirsch-Reinshagen, V., Wellington, C. L., Bales, K. R., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33622 · Cited by 407
Apolipoprotein E, Receptors, and Modulation of Alzheimer’s Disease
Zhao, N., Liu, C.-C., Qiao, W., & Bu, G. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.003 · Cited by 370
Delayed cerebral ischaemia after subarachnoid haemorrhage: looking beyond vasospasm
Rowland, M. J., Hadjipavlou, G., Kelly, M., Westbrook, J., & Pattinson, K. T. S. (2012) · British Journal of Anaesthesia · doi:10.1093/bja/aes264 · Cited by 357
APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease
Fortea, J., Pegueroles, J., Alcolea, D., Belbin, O., Dols-Icardo, O., Vaqué-Alcázar, L., Videla, L., Gispert, J. D., Suárez-Calvet, M., Johnson, S. C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02931-w · Cited by 369
Finder, V. H., & Glockshuber, R. (2007) · Neurodegenerative Diseases · doi:10.1159/000100355 · Cited by 348
Ayton, S., Faux, N. G., Bush, A. I., Initiative, A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., Jagust, W., Trojanowki, J. Q., et al. (2015) · Nature Communications · doi:10.1038/ncomms7760 · Cited by 327
Nelson, P. T., Head, E., Schmitt, F. A., Davis, P. R., Neltner, J. H., Jicha, G. A., Abner, E. L., Smith, C. D., Van Eldik, L. J., Kryscio, R. J., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0826-y · Cited by 365
“By far, the strongest risk factor for late-onset AD is the e4 allele of the APOE gene [52, 213].”
Microglia: Agents of the CNS Pro-Inflammatory Response
Rodríguez-Gómez, J. A., Kavanagh, E., Engskog-Vlachos, P., Engskog, M. K. R., Herrera, A. J., Espinosa-Oliva, A. M., Joseph, B., Hajji, N., Venero, J. L., & Burguillos, M. A. (2020) · Cells · doi:10.3390/cells9071717 · Cited by 365
Liu, Q., Zerbinatti, C. V., Zhang, J., Hoe, H.-S., Wang, B., Cole, S. L., Herz, J., Muglia, L., & Bu, G. (2007) · Neuron · doi:10.1016/j.neuron.2007.08.008 · Cited by 364
Buttini, M., Orth, M., Bellosta, S., Akeefe, H., Pitas, R. E., Wyss-Coray, T., Mucke, L., & Mahley, R. W. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-04867.1999 · Cited by 360
“Of the three common apoE isoforms in humans (Utermann et al., 1977), apoE4 is a major risk factor for Alzheimer’s disease (AD) (Corder et al., 1993; Strittmatter et al., 1993; Mayeux et al., 1995; Farrer et al., 1997) and for poor outcome after acute head injury (Nicoll et al., 1996; Teasdale et…”
BackgroundShih, R. A., Belmonte, P. L., & Zandi, P. P. (2004) · International Review of Psychiatry · doi:10.1080/09540260400014401 · Cited by 340
“The only consistently identified genetic risk factor for late-onset AD is the APOE e4 allele (apolipoprotein e4) (Corder et al., 1993; Jarvik et al., 1995; Levy-Lahad et al., 1998).”
BackgroundTherapeutic approaches to Alzheimer's disease
Klafki, H.-W., Staufenbiel, M., Kornhuber, J., & Wiltfang, J. (2006) · Brain · doi:10.1093/brain/awl280 · Cited by 362
“, 1986), which is the major genetic risk factor for Alzheimer’s disease (Corder et al., 1993; Poirier et al., 1993).”
BackgroundLarge-scale genomics unveils the genetic architecture of psychiatric disorders
Gratten, J., Wray, N. R., Keller, M. C., & Visscher, P. M. (2014) · Nature Neuroscience · doi:10.1038/nn.3708 · Cited by 363
Detecting Marker-Disease Association by Testing for Hardy-Weinberg Disequilibrium at a Marker Locus
Nielsen, D. M., Ehm, M. G., & Weir, B. S. (1998) · The American Journal of Human Genetics · doi:10.1086/302114 · Cited by 366
“To proceed with the localization of a gene involved in this disease, Feder et al. (1996) developed 45 short tandem-repeat polymorphism and single nucleotide polymorphism (SNP) markers lying within an 8-cM region suspected to contain the gene. All 45 markers were typed in 101 HH patients and 64 controls. To estimate th…”
BackgroundMethodInfluentialMartin, E. R., Lai, E. H., Gilbert, J. R., Rogala, A. R., Afshari, A. J., Riley, J., Finch, K. L., Stevens, J. F., Livak, K. J., Slotterbeck, B. D., et al. (2000) · The American Journal of Human Genetics · doi:10.1086/303003 · Cited by 358
“Furthermore, there is a complex relationship between the APOE-4 genotype and disease status, with the APOE-4 allele being neither necessary nor sufficient for AD but, instead, modulating the risk for development of AD (Corder et al. 1993, 1994).”
BackgroundSelf-citationCholesterol Modulates α-Secretase Cleavage of Amyloid Precursor Protein
Bodovitz, S., & Klein, W. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4436 · Cited by 359
“The E4 allele of ApoE is associated with higher plasma cholesterol levels (Sing and Davignon, 1985), and ApoE4 is present with increased frequency in patients with sporadic and late onset familial AD (Strittmatter et al., 1993; Saunders et al., 1993; Corder et al., 1993).”
BackgroundReduced grid-cell–like representations in adults at genetic risk for Alzheimer’s disease
Kunz, L., Schröder, T. N., Lee, H., Montag, C., Lachmann, B., Sariyska, R., Reuter, M., Stirnberg, R., Stöcker, T., Messing-Floeter, P. C., et al. (2015) · Science · doi:10.1126/science.aac8128 · Cited by 347
Midkine and pleiotrophin in neural development and cancer
Kadomatsu, K., & Muramatsu, T. (2004) · Cancer Letters · doi:10.1016/s0304-3835(03)00450-6 · Cited by 354
“[85] E.”
Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau
Hardy, J., Duff, K., Hardy, K. G., Perez-Tur, J., & Hutton, M. (1998) · Nature Neuroscience · doi:10.1038/1565 · Cited by 347
“and APP metabolism or Ab deposition, even though genetic variability in APOE is a major risk factor for A”
BackgroundPalaniappan, L. P., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Currie, M. E., Earlie, R. S., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001412 · Cited by 242
A full genome scan for late onset Alzheimer's disease
Kehoe, P. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.2.237 · Cited by 357
“The ε4 allele of APOE, although neither necessary nor sufficient to cause AD, is associated with increased risk of both early and late onset disease (7).”
Cordy, J. M., Hussain, I., Dingwall, C., Hooper, N. M., & Turner, A. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1635130100 · Cited by 356
Cataldo, A., Hamilton, D., Barnett, J., Paskevich, P., & Nixon, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-01-00186.1996 · Cited by 359
“APOE, another important molecule implicated in Alzheimer's disease (Corder et al., 1993; Strittmatter et al., 1993), is synthesized by astrocytes and taken up by neurons in markedly increased amounts in response to various forms of neuronal injury, presumably to provide cholesterol for new membrane…”
BackgroundMandrekar-Colucci, S., Karlo, J. C., & Landreth, G. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5268-11.2012 · Cited by 355
“Apolipoprotein E (apoE) is the principal genetic risk factor for sporadic, late-onset AD (Corder et al., 1993; Roses, 1996). apoE is synthesized mainly by astrocytes and plays an isoform-dependent role in modulating A fibrillization and clearance (Holtzman, 2001; Zlokovic et al., 2005; Kim et al.,…”
BackgroundChakrabarty, P., Li, A., Ceballos-Diaz, C., Eddy, J. A., Funk, C. C., Moore, B., DiNunno, N., Rosario, A. M., Cruz, P. E., Verbeeck, C., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.11.020 · Cited by 354
(1997) · Europe PMC (PubMed Central) · Cited by 354
Cholesterol in Alzheimer's disease
Shobab, L. A., Hsiung, G.-Y. R., & Feldman, H. H. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70248-9 · Cited by 336
Lopera, F. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340027028 · Cited by 351
Cai, Y., Liu, J., Wang, B., Sun, M., & Yang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.856376 · Cited by 351
“Compelling evidence reveals that APOE immunoreactivity widely overlaps with senile plaques (SPs) and neurofibrillary tangles, and more SPs were found in patients with APOE 4 than APOE 3 (65, 66).”
BackgroundAPOE distribution in world populations with new data from India and the UK
Singh, P. P., Singh, M., & Mastana, S. S. (2006) · Annals of Human Biology · doi:10.1080/03014460600594513 · Cited by 351
“Various clinical and epidemiological studies have highlighted the functional consequences of the phenotype–genotype relationship of APOE and its affiliation with diverse pathological conditions and cognitive traits (Mahley 1988; Rinder et al. 1991; Corder et al. 1993; Schachter et al. 1994; Stannard et al. 2001; Hsu e…”
BackgroundUsefulness of MRI measures of entorhinal cortex versus hippocampus in AD
de Leon, M., Bobinski, M., Convit, A., Wolf, O., & Insausti, R. (2001) · Neurology · doi:10.1212/wnl.56.6.820 · Cited by 348
Holtzman, D. M., Pitas, R. E., Kilbridge, J., Nathan, B., Mahley, R. W., Bu, G., & Schwartz, A. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.21.9480 · Cited by 349
Brain Glutathione Levels – A Novel Biomarker for Mild Cognitive Impairment and Alzheimer’s Disease
Mandal, P. K., Saharan, S., Tripathi, M., & Murari, G. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.04.005 · Cited by 336
“Furthermore, the extent of GSH reduction in AD has been shown to be dependent on the presence and number of the 4 allele of Apolipoprotein E, an allele associated with earlier and more severe expression of AD pathology (24), with GSH”
MCI conversion to dementia and the APOE genotype: A prediction study with FDG-PET
Mosconi, L., Perani, D., Sorbi, S., Herholz, K., Nacmias, B., Holthoff, V., Salmon, E., Baron, J.-C., De Cristofaro, M. T. R., Padovani, A., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000147469.18313.3b · Cited by 343
Tau and neuroinflammation: what impact for Alzheimer's disease and tauopathies?
Laurent, C., Buée, L., & Blum, D. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.01.003 · Cited by 348
“[60] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al.”
BackgroundBeyond the neuron–cellular interactions early in Alzheimer disease pathogenesis
Henstridge, C. M., Hyman, B. T., & Spires-Jones, T. L. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0113-1 · Cited by 348
Pratic�, D., Clark, C. M., Lee, V. M.-Y., Trojanowski, J. Q., Rokach, J., & FitzGerald, G. A. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200011)48:5<809::aid-ana19>3.0.co;2-9 · Cited by 348
The genetics of multiple sclerosis: SNPs to pathways to pathogenesis
Oksenberg, J. R., Baranzini, S. E., Sawcer, S., & Hauser, S. L. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2395 · Cited by 347
Apolipoprotein E: an important gene and protein to follow in laboratory medicine
Siest, G., Pillot, T., Régis-Bailly, A., Leininger-Muller, B., Steinmetz, J., Galteau, M. M., & Visvikis, S. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.8.1068 · Cited by 347
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
Sano, M., Bell, K. L., Galasko, D., Galvin, J. E., Thomas, R. G., van Dyck, C. H., & Aisen, P. S. (2011) · Neurology · doi:10.1212/wnl.0b013e318228bf11 · Cited by 336
Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22.
Wilhelmsen, K. C., Lynch, T., Pavlou, E., Higgins, M., & Nygaard, T. G. (1994) · PubMed Central · Cited by 396
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
Riddell, D. R., Zhou, H., Atchison, K., Warwick, H. K., Atkinson, P. J., Jefferson, J., Xu, L., Aschmies, S., Kirksey, Y., Hu, Y., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1972-08.2008 · Cited by 346
“Patients expressing the 4 allele have an earlier age at onset, a greater amyloid burden and reduced capacity for synaptic plasticity (Corder et al., 1993, 2004; Ji et al., 2003; Lai et al., 2006).”
BackgroundCardiovascular disease and Alzheimer's disease: common links
STAMPFER, M. J. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01687.x · Cited by 324
Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments
Reiman, E. M., Langbaum, J. B. S., Fleisher, A. S., Caselli, R. J., Chen, K., Ayutyanont, N., Quiroz, Y. T., Kosik, K. S., Lopera, F., & Tariot, P. N. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-0059 · Cited by 339
“Before we describe the API in more detail, we briefly summarize relevant biomarker and cognitive findings from our ongoing longitudinal study of cognitively normal people with two copies, one copy and no copies of the apolipoprotein E (APOE) ε4 allele, the major late-onset AD susceptibility gene[42].”
The complexity of Alzheimer’s disease: an evolving puzzle
Ferrari, C., & Sorbi, S. (2021) · Physiological Reviews · doi:10.1152/physrev.00015.2020 · Cited by 309
Beecham, G. W., Hamilton, K., Naj, A. C., Martin, E. R., Huentelman, M., Myers, A. J., Corneveaux, J. J., Hardy, J., Vonsattel, J.-P., Younkin, S. G., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004606 · Cited by 343
“The ADGC, together with international collaborators under the banner of IGAP (International Genomics of Alzheimer’s Project) has to-date identified 21 common genetic loci associated with AD dementia using primarily clinically ascertained datasets [7,8,10,11], in addition to confirming the APOE locus [12].”
MethodSelf-citationGenetic Classification of Primary Neurodegenerative Disease
Hardy, J., & Gwinn-Hardy, K. (1998) · Science · doi:10.1126/science.282.5391.1075 · Cited by 343
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- University of California, Los Angeles (US)
- Massachusetts General Hospital (US)
- Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710.
- Venue
- Science
- Published
- 1993-08-13
- Volume
- 261
- Issue
- 5123
- Pages
- 921-923
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2036362108
- Cited by
- 9,429
- References
- 16
- Citations by year
- 2026: 289 · 2025: 380 · 2024: 355 · 2023: 328 · 2022: 356 · 2021: 378 · 2020: 396 · 2019: 358 · 2018: 341 · 2017: 343 · 2016: 345 · 2015: 303 · 2014: 343 · 2013: 335 · 2012: 333
- FWCI
- 135.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, gene dosage, Alzheimer's disease, genetic risk, homozygosity, age of onset, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Homozygote, Humans, Male, Risk Factors, Linkage Disequilibrium, Survival Rate, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.